Intermittent Therapy With The BTK Inhibitor Acalabrutinib (Calquence) In Combination With Obinutuzumab In Treatment Naïve (Tn) Patients With Chronic Lymphocytic Leukemia (CLL)
MD Anderson Study Status
This phase II trial investigates the how well acalabrutinib and obinutuzumab work in treating patients with chronic lymphocytic leukemia (CLL). Acalabrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with obinutuzumab may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving acalabrutinib and obinutuzumab may help to control disease progression in CLL patients who have not received treatment for CLL.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.